Full-Time

Phlebotomist

Healthcare of Greater Washington

Updated on 8/6/2026

Sonic Healthcare USA

Sonic Healthcare USA

51-200 employees

Laboratory and pathology testing services

No salary listed

Oxon Hill, MD, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Phlebotomy

Get referred to Sonic Healthcare USA

See people who can refer or advise you

Requirements
  • A high school diploma or equivalent is required.
  • Previous phlebotomy training or experience is required.
  • Excellent communication skills are required.
  • The ability to work in a fast-paced environment is required.
  • Basic computer and data entry skills are required.
  • Employees must maintain strict confidentiality and comply with applicable privacy and security standards when accessing Protected Health Information.
Responsibilities
  • Provide patient care and customer-focused service.
  • Perform venipuncture on patients of all ages.
  • Collect and prepare non-blood specimens.
  • Ensure proper specimen processing, labeling, and test ordering.
  • Champion safety, compliance, and quality control.
Desired Qualifications
  • Two or more years of laboratory training or experience in specimen collection and processing.
  • Certification from the American Society of Phlebotomy Technicians.

Sonic Healthcare USA provides laboratory testing and professional pathology services across the United States as part of Sonic Healthcare Limited, one of the world’s largest medical diagnostics groups. It operates through nine divisions and around eight thousand employees, following a federated model that puts medical leadership at the local level to ensure high-quality, community-based testing for doctors and patients. Its tests cover core diagnostic laboratory services and pathology expertise used by medical practitioners, hospitals, and community health services. The company aims to deliver precise, timely results and strong clinical partnerships to improve patient care by offering comprehensive laboratory testing and pathology support while maintaining close ties to local healthcare providers.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Austin, Texas

Founded

2014

Get referred to Sonic Healthcare USA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • February 2026 Sonic expanded advanced diagnostics by combining Cairo, ThyroSeq, and nationwide distribution.
  • The 2026 US operating review targets nine anatomical pathology practices to improve profitability.
  • July 2026 PathologyWatch handled over 60% of dermatopathology volume, lifting productivity and turnaround.

What critics are saying

  • February 2026 Sonic cited low organic growth and restructuring costs for weaker US margins.
  • Sonic completed Alabama wind-down after losing a major payer contract, exposing reimbursement fragility.
  • PAMA fee cuts and failed integration can crush US lab economics by 2026.

What makes Sonic Healthcare USA unique

  • Sonic’s medical leadership model pairs local labs with national logistics and payer contracting.
  • August 2025 Cairo Diagnostics added hematology-oncology depth to Sonic’s US specialty network.
  • May 2026 Austin validation work made Sonic a gateway for new laboratory-developed tests.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Company News

Daily Dispatch
May 28th, 2026
BCAL Diagnostics and Sonic Healthcare advance validation of BreastestPlus Version 2 for US market.

BCAL Diagnostics and Sonic Healthcare advance validation of BreastestPlus Version 2 for US market. BCAL Diagnostics (ASX:BDX) has taken a step toward bringing its flagship blood test to the United States by signing a Validation Agreement with Sonic Healthcare USA. The agreement calls for BreastestPlus Version 2 to be transferred to Sonic's CLIA-certified Sonic Reference Laboratory in Austin, Texas, where the assay will be optimised and validated for the US market. The move follows BCAL's aim to establish BreastestPlus Version 2 as a Laboratory Developed Test in the US, a pathway the company describes as the fastest and most efficient route for US market entry. The US breast cancer diagnostics market is large and growing, with more than 40 million mammograms performed annually and roughly 376,000 new breast cancer cases each year. BCAL said successful validation at Sonic's facility would represent a key milestone on that pathway and could lead to commercial licensing discussions between the two organisations. BCAL said it also continues to collect clinical samples from patients across the US in collaboration with leading breast cancer specialists. Those samples will support BCAL's Clinical Outcomes studies, which the company says are necessary for regulatory and reimbursement submissions. Shane Ryan, Chief Executive Officer, BCAL, said, "This Validation Agreement with Sonic Healthcare USA is an important milestone for BCAL Diagnostics and our US commercialisation strategy. Sonic's CLIA-certified laboratory infrastructure and deep expertise in clinical diagnostics provide the right environment to validate BreastestPlus(TM) Version 2. What excites me most is what this brings together - two highly capable teams, united by a shared purpose of delivering better diagnostic solutions for women at scale. We look forward to progressing through the validation process and advancing towards commercial deployment in the world's largest breast cancer diagnostics market." Dr Mohamed Salama, Chief Medical Officer, Sonic Healthcare USA, said, "Sonic Healthcare USA is committed to advancing access to innovative diagnostic solutions that make a real difference to patients. The validation of BreastestPlus(TM) Version 2 at our CLIA-certified Sonic Reference Laboratory in Austin, Texas, reflects that commitment, and we look forward to assessing its performance through a rigorous validation process." The financial terms of the Validation Agreement were not disclosed.

Newswise
Aug 22nd, 2025
Sonic Healthcare USA, Inc. Announces Acquisition of Cairo Diagnostics LLC to Expand Sonic's National Hematology Oncology Testing Capabilities

Sonic Healthcare USA, Inc. announces acquisition of Cairo Diagnostics LLC to expand Sonic's national hematology oncology testing capabilities.

PR Newswire
Aug 22nd, 2025
Sonic Healthcare Acquires Cairo Diagnostics

Sonic Healthcare USA, Inc. has acquired Cairo Diagnostics LLC to enhance its national hematology oncology testing capabilities. Founded by Dr. Sherif Ibrahim, Cairo is known for its integrated oncology testing approach, combining various diagnostic methods to provide comprehensive reports. This acquisition aims to expand Sonic's reach and improve service to oncologists nationwide, offering faster and more complete diagnostic solutions.

The West Australian
Mar 20th, 2024
Sonic Healthcare beefs up Swiss presence with $202m purchase of laboratory group Dr Risch

Sonic Healthcare will beef up its presence in Switzerland with the purchase of laboratory group Dr Risch for 117 million Swiss francs ($202m).

Business News Australia
Apr 27th, 2023
Sonic announces $611m in German acquisitions in April

Australias largest pathology company has today announced its second German acquisition this month, with binding agreements signed to purchase Medical Laboratori